Developing a new framework for dose calculation

Journal of Clinical Oncology

Volumn 24, Issue 10, 2006, Pages 1489-1490

  Gurney, Howard ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; METHOTREXATE; NAVELBINE; PACLITAXEL; PLATINUM;

AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; BREAST CANCER; DOSE RESPONSE; DRUG BINDING; DRUG CLEARANCE; DRUG USE; EDITORIAL; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; SEPSIS; BODY SURFACE; NOTE;

ANTINEOPLASTIC AGENTS; BODY SURFACE AREA; CISPLATIN; HUMANS;

EID: 33645735425     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.1607     Document Type: Editorial

References (12)

1. Gurney H: Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J Clin Oncol 14:2590-2611, 1996
2. Baker SD, Verweij J, Rowinsky EK, et al: Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 94:1883-1888, 2002
3. Sparreboom A: BSA-based dosing and alternative approaches. Clin Adv Hematol Oncol 3:448-450, 2005
4. Gurney H: How to calculate the dose of chemotherapy. Br J Cancer 86:1297-1302, 2002
5. Loos WJ, de Jongh FE, Sparreboom A, et al: Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol 24:1499-1506, 2006
6. de Jongh FE, Verweij J, Loos WJ, et al: Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19:3733-3739, 2001
7. Wong M, Balleine RL, Blair EYL, et al: Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol (in press)
8. Colleoni M, Li S, Gelber RD, et al: Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 366:1108-1110, 2005
9. Griggs JJ, Sorbero ME, Lyman GH: Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 165:1267-1273, 2005
10. Gurney H: I don't underdose my patients do I? Lancet Oncol 6:637-638, 2005
11. Di Maio M, Gridelli C, Gallo C, et al: Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: A pooled analysis of three randomised trials. Lancet Oncol 6:669-677, 2005
12. Andersson T, Flockhart DA, Goldstein DB, et al: Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 78:559-581, 2005